Vaxart, Inc. (NASDAQ:VXRT) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET

Company Participants

Brant Biehn - SVP, Business Operations

Cezar Floroiu - CEO, President & Director

Sean Tucker - SVP & Chief Scientific Officer

James Cummings - Chief Medical Officer

Conference Call Participants

Pete Stavropoulos - Cantor Fitzgerald

Sahil Kazmi - B. Riley Securities FBR

Operator

Greetings, and welcome to the Vaxart's Third Quarter 2022 Business Update and Financial Results Conference Call. A question-and-answer session will follow management's opening remarks. [Operator Instructions]. As a reminder, this conference is being recorded.

I would now like to turn the webcast over to your host, Brant Biehn, Senior Vice President, Business Operations.

Brant Biehn

Good afternoon, and welcome to today's call. Joining us from Vaxart are Andrei Floroiu, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; and Dr. James Cummings, Chief Medical Officer.

Before we get started, I would like to remind everyone that this conference call -- that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.

Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, the extent and duration of the impact of the COVID-19 pandemic and other risks described in the Risk Factors section of Vaxart's most recently filed annual report on Form 10-K and other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after this call, except as required by law.

I'll now turn the call over to Andrei Floroiu. Andrei?

Cezar Floroiu

Thank you. And thank you to everyone for joining us today. We are pleased to have this opportunity to review with you our third quarter progress and showcase the transformational potential of our oral vaccine platform. I'd like to start with the financial update that I believe is of interest to our investors.

In August of this year, our shareholders approved our proxy proposal that authorize an increase in our authorized shares by 100 million to 250 million shares. During the proxy voting process, many of our individual shareholders were concerned that passing this proposal would lead to an immediate and significant dilution. I'd like to put that concern to rest.